Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 344.31 is 180% above its 3-year average of 122.88, near the high end of its 3-year range (9.88–344.31).
As of the fiscal period ended Wednesday, December 31, 2025. 51.27% above its 12-month average of 227.61.
Reported quarterly current ratio; no daily interpolation. Q4 FY2025 (2025-12-31): 344.31.
CURRENT RATIO
344.31
CURRENT RATIO AVG TTM
227.61
CURRENT RATIO AVG 3Y
122.88
CURRENT RATIO AVG 5Y
N/A
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+51.27%
CURRENT VS 3Y AVG
+180.21%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+9081.61%
vs the sector median at left
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$215.07M
Current Ratio
344.31
TTM Avg
227.61
3Y Avg
122.88
5Y Avg
N/A
Market Cap
$214.46M
Current Ratio
20.05
TTM Avg
17.55
3Y Avg
12.54
5Y Avg
12.54
Market Cap
$216.91M
Current Ratio
4.07
TTM Avg
3.65
3Y Avg
6.88
5Y Avg
10.38
Market Cap
$218.30M
Current Ratio
21.96
TTM Avg
18.45
3Y Avg
17.11
5Y Avg
21.15
Market Cap
$210.98M
Current Ratio
5.36
TTM Avg
6.17
3Y Avg
11.50
5Y Avg
11.99
Market Cap
$210.41M
Current Ratio
10.89
TTM Avg
11.84
3Y Avg
8.89
5Y Avg
15.32
Market Cap
$220.93M
Current Ratio
6.45
TTM Avg
11.52
3Y Avg
11.11
5Y Avg
13.89
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $215.07M | 344.31 | 227.61 | 122.88 | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | 20.05 | 17.55 | 12.54 | 12.54 |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 6.50 | 4.21 | 3.36 | 3.03 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | 4.07 | 3.65 | 6.88 | 10.38 |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | 21.96 | 18.45 | 17.11 | 21.15 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | 5.36 | 6.17 | 11.50 | 11.99 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | 10.89 | 11.84 | 8.89 | 15.32 |
| Compugen Ltd. (CGEN)vs › | $209.91M | 5.72 | 5.91 | 5.85 | 7.15 |
| Profound Medical Corp. (PROF)vs › | $220.93M | 6.45 | 11.52 | 11.11 | 13.89 |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
Current Ratio
344.31
Quick Ratio
344.31
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 344.31 |
| 2025-09-30 | 344.31 |
| 2025-06-30 | 211.10 |
| 2024-12-31 | 10.71 |
| 2024-06-30 | 35.56 |
| 2023-12-31 | 15.86 |
| 2023-06-30 | 11.29 |
| 2022-12-31 | 9.88 |
